GlassScriptPhysician profile
Subhi Sbahi
NPI 1306843412
$7,382.37
in general payments reported to CMS, 2019-2025
42 companies · $1,274 in 2025
The $1,274 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $1,712 · 2021: $760 · 2022: $770 · 2023: $822 · 2024: $755 · 2025: $1,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,851.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,210.67 | 2019-2025 | Perclose Prostyle |
| Amgen INC. | $860.71 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $803.50 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $629.36 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $556.83 | 2019-2024 | Xarelto |
| Pfizer INC. | $402.31 | 2019-2025 | |
| Boston Scientific Corporation | $345.07 | 2019-2025 | Farapulse, Watchman Flx, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $331.14 | 2019-2025 | Farxiga, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $282.50 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $236.85 | 2019-2022 | |
| Glaxosmithkline, LLC. | $148.50 | 2025 | Nucala, Arexvy |
| Amarin Pharma, INC. | $141.81 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $130.78 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $126.66 | 2019-2020 | |
| Chiesi USA, INC. | $120.43 | 2022-2025 | Kengreal, Cleviprex |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhi Sbahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.